INOVIO PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Liabilities
INOVIO PHARMACEUTICALS, INC. (INO) reported Increase (Decrease) in Accrued Liabilities of -$1.17 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2019-11-12
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2019-09-30 was -$137.50K.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2019-06-30 was -$2.52M, a 230.55% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2019-03-31 was $1.49M.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-12-31 was -$1.68M, a 343.01% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2018 was -$2.94M, a 231.05% decline from fiscal 2017.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2017 was $2.24M, a 40.46% decline from fiscal 2016.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2016 was $3.77M, a 535.34% increase from fiscal 2015.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2015 was $593.05K, a 5.67% increase from fiscal 2014.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2019-09-30 | -$137.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$2.66M derived: sum of 2 quarters · filed 2019-11-12 | -$1.17M 10-Q · filed 2019-11-12 | -$2.85M derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-06-30 | -$2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$1.03M 10-Q · filed 2019-08-08 | -$2.71M derived: sum of 3 quarters · filed 2019-08-08 | -$5.72M derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-03-31 | $1.49M 10-Q · filed 2019-05-09 | -$193.81K derived: sum of 2 quarters · filed 2019-05-09 | -$3.20M derived: sum of 3 quarters · filed 2019-11-12 | -$1.27M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-12-31 | -$1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$4.69M derived: sum of 2 quarters · filed 2019-11-12 | -$2.76M derived: sum of 3 quarters · filed 2019-11-12 | -$2.94M 10-K · filed 2019-03-12 |
| 2018-09-30 | -$3.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$1.08M derived: sum of 2 quarters · filed 2019-11-12 | -$1.26M 10-Q · filed 2019-11-12 | -$566.99K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.75M 10-Q · filed 2019-08-08 | $2.44M derived: sum of 3 quarters · filed 2019-08-08 | $3.17M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | -$183.01K 10-Q · filed 2019-05-09 | $508.84K derived: sum of 2 quarters · filed 2019-05-09 | $1.24M derived: sum of 3 quarters · filed 2019-05-09 | $2.52M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $691.85K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $1.42M derived: sum of 2 quarters · filed 2019-03-12 | $2.70M derived: sum of 3 quarters · filed 2019-03-12 | $2.24M 10-K · filed 2019-03-12 |
| 2017-09-30 | $731.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.01M derived: sum of 2 quarters · filed 2018-11-08 | $1.55M 10-Q · filed 2018-11-08 | $703.78K derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $820.36K 10-Q · filed 2018-08-07 | -$27.52K derived: sum of 3 quarters · filed 2019-03-12 | $2.18M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | -$458.52K 10-Q · filed 2018-05-09 | -$1.31M derived: sum of 2 quarters · filed 2019-03-12 | $903.59K derived: sum of 3 quarters · filed 2019-03-12 | $1.76M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$847.88K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $1.36M derived: sum of 2 quarters · filed 2019-03-12 | $2.22M derived: sum of 3 quarters · filed 2019-03-12 | $3.77M 10-K · filed 2019-03-12 |
| 2016-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $3.07M derived: sum of 2 quarters · filed 2017-11-08 | $4.62M 10-Q · filed 2017-11-08 | $4.27M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $855.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $2.41M 10-Q · filed 2017-08-08 | $2.06M derived: sum of 3 quarters · filed 2018-03-14 | $2.46M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $1.55M 10-Q · filed 2017-05-10 | $1.21M derived: sum of 2 quarters · filed 2018-03-14 | $1.60M derived: sum of 3 quarters · filed 2018-03-14 | $2.88M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | -$341.96K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $54.00K derived: sum of 2 quarters · filed 2018-03-14 | $1.33M derived: sum of 3 quarters · filed 2018-03-14 | $593.05K 10-K · filed 2018-03-14 |
| 2015-09-30 | $395.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $1.68M derived: sum of 2 quarters · filed 2016-11-09 | $935.01K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $539.05K 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | -$740.55K 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $561.25K 10-K · filed 2017-03-15 | |||
| 2013-12-31 | $40.28K 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |